Validations: Biosimilar Process & Analytical Comparability
Assay Transfers Across Sites: Bias and Parity Assay Transfers Across Sites: Bias and Parity Introduction to Biosimilar Analytical Comparability The pharmaceutical industry increasingly relies on biosimilars to improve patient access to biologic therapies. Ensuring biosimilar analytical comparability is crucial for regulatory approvals, as it demonstrates that the biosimilar product is similar in quality, safety, and efficacy to the reference biologic….
Forced Degradation to Map CQAs: Stressors and Readouts Forced Degradation to Map CQAs: Stressors and Readouts Introduction to Biosimilar Analytical Comparability The development of biosimilars is increasingly vital in meeting the rising global demand for biologic therapies. Ensuring biosimilar analytical comparability is a regulatory requirement under guidelines from authorities such as the FDA and EMA. Central to this process is…
Lot Release vs Characterization: What Goes Where Lot Release vs Characterization: What Goes Where The process of ensuring biosimilarity between a biosimilar product and its reference biological drug requires a comprehensive understanding of the analytical approaches employed for comparability assessment. This tutorial serves as a guide for pharmaceutical professionals in accurately mapping Critical Quality Attributes (CQA) to fingerprint analytics through…
Reference Standard Strategy: Bridging When Materials Change Reference Standard Strategy: Bridging When Materials Change The development and regulatory approval of biosimilars rely heavily on analytical comparability to ensure that they are structurally, functionally, and safety-wise equivalent to their reference product. This article delves into the concept of biosimilar analytical comparability with a specific focus on critical quality attributes (CQA) mapping,…
Orthogonal Method Sets: Showing Robust Similarity Orthogonal Method Sets: Showing Robust Similarity Introduction to Biosimilar Analytical Comparability The approval of biosimilars represents a significant advancement in healthcare, offering alternatives to biologic therapies while maintaining safety and efficacy. One of the most critical aspects of biosimilar development is analytical comparability, which ensures that the biosimilar is similar to its reference product…
Matrix Effects and Interferences in Biosimilar Assays Matrix Effects and Interferences in Biosimilar Assays In the realm of biopharmaceuticals, ensuring the analytical comparability of biosimilars remains a critical aspect of development. The regulatory frameworks defined by the FDA, EMA, and MHRA highlight the need for stringent methodologies in evaluating biosimilar drugs. This guide provides a comprehensive step-by-step tutorial focused on…
Higher-Order Structure: CD, FTIR, and DSC—Validation Hooks Higher-Order Structure: CD, FTIR, and DSC—Validation Hooks Biosimilar analytical comparability represents a crucial aspect in the development and post-marketing of biosimilars, especially concerning compliance with regulatory requirements set forth by authorities like the FDA, EMA, and MHRA. Understanding higher-order structures, including the use of Circular Dichroism (CD), Fourier Transform Infrared Spectroscopy (FTIR), and…
Aggregation & Subvisible Particles: AUC, SEC-MALS, Flow Imaging Aggregation & Subvisible Particles: AUC, SEC-MALS, Flow Imaging Biosimilars have become a critical segment in the biopharmaceutical domain, necessitating a thorough approach to analytical comparability. Regulatory bodies such as the US FDA, EMA, and MHRA require rigorous CQA mapping and fingerprint analytics to ensure that biosimilars exhibit equivalence to reference products. This…
Bioassay Similarity: Potency Models and Equivalence Bounds Bioassay Similarity: Potency Models and Equivalence Bounds Introduction to Biosimilar Analytical Comparability Biosimilar development presents various challenges, particularly with respect to ensuring biosimilar analytical comparability. Understanding how to demonstrate analytical equivalence between the reference product and its biosimilar counterpart is a critical step in gaining regulatory approval in various markets, including the US…
Impurity Profiles: Process-Related vs Product-Related Impurity Profiles: Process-Related vs Product-Related In the ever-evolving landscape of biosimilars, ensuring analytical comparability is a cornerstone of regulatory success. This guide provides a structured approach to understanding impurity profiles in the context of biosimilar analytical comparability. The focus will be on distinguishing between process-related and product-related impurities while employing techniques like CQA mapping and…